GlassScriptPhysician profile
Dean L Ross
NPI 1952347361
$3,115.11
in general payments reported to CMS, 2019-2025
32 companies · $81.33 in 2025
The $81.33 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,076 · 2020: $265 · 2021: $24.23 · 2022: $158 · 2023: $1,158 · 2024: $352 · 2025: $81.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,542 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,542.06 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $378.45 | 2019-2024 | |
| Novo Nordisk INC | $316.75 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $310.41 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $286.61 | 2019-2024 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.49 | 2019-2023 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $184.49 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $162.46 | 2019-2024 | Prolia, Evenity, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $161.62 | 2019-2023 | Gattex |
| Abbott Laboratories | $152.12 | 2023-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $141.79 | 2019-2020 | |
| Abbvie INC. | $112.99 | 2023-2025 | Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.60 | 2019-2020 | |
| Allergan, INC. | $81.86 | 2019 | |
| Sanofi-Aventis U.S. LLC | $66.16 | 2019-2023 | |
| Exact Sciences Corporation | $57.71 | 2023-2024 | Cologuard Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $50.00 | 2023 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $49.77 | 2023 | |
| Nevro Corp. | $25.13 | 2023 | Senza |
| Bausch Health US, LLC | $24.53 | 2025 | Wellbutrin |
| Vanda Pharmaceuticals INC. | $24.23 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $24.00 | 2023 | |
| Eisai INC. | $23.23 | 2024 | |
| Corcept Therapeutics | $22.58 | 2023 | Korlym |
| Celgene Corporation | $20.85 | 2019 | |
| Hologic Sales and Service, LLC | $19.92 | 2024 | Thinprep 2000 Processor, Aptima |
| Novartis Pharmaceuticals Corporation | $18.55 | 2019 | |
| Medtronic Minimed, INC. | $17.60 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.08 | 2022 | |
| Dexcom, INC. | $13.88 | 2023 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $13.26 | 2024 | Voquezna |
| Antares Pharma, INC. | $12.20 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.